Clone j43

Manufactured by BioXCell

Sourced in United States

The Clone J43 is a laboratory instrument designed for cell cloning and selection. It provides a controlled environment for the isolation, expansion, and screening of individual cell lines. The core function of the Clone J43 is to facilitate the clonal selection and propagation of cells of interest, enabling researchers to obtain genetically homogeneous cell populations for further analysis and experimentation.

Automatically generated - may contain errors

Lab products found in correlation

Anti cd8 clone 53, by BioXCell (2 mentions) Clone 9d9, by BioXCell (2 mentions) Signa excite hdx, by GE Healthcare (1 mentions)

3 protocols using clone j43

Tumor Regression in Mouse Models with STB-C017 and Checkpoint Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols

Tumors were implanted via subcutaneous injection of 2 × 10⁵ CT26 or CT26-TDO cells into the right flank of wild type BALB/c mice. When tumor volume reached >50 mm³, mice were orally administrated STB-C017 twice daily. Mice in the control group were orally treated with the same volume of PBS. For combination therapy, we also administered epacadostat orally (100 mg/kg, EPA, LEAPChem) twice daily. For the cell depletion study, the mice received an intraperitoneal injection of 200 μg of anti-CD8 (clone 53–6.72, BioXCell) antibody every 3 days. For immune checkpoint blockade, each mouse received an intraperitoneal injection of anti-PD-1 (8 mg/kg, clone J43, BioXCell) or anti-CTLA-4 (4 mg/kg, clone 9D9, BioXCell) antibody at the given time points. The surviving mice with complete tumor regression were rechallenged with 2 × 10⁵ CT26 or Renca cells in the left flank, and the tumor growth was monitored. The tumors were measured with a digital caliper, and tumor volumes were calculated using the following modified ellipsoid formula: 1/2 × (length × width^{2 (link)}). For survival analysis, the mice were euthanized when the tumor volume exceeded 2000 mm³ or when the mice became moribund.

Kim J.H., Lee W.S., Lee H.J., Yang H., Lee S.J., Kong S.J., Je S., Yang H.J., Jung J., Cheon J., Kang B., Chon H.J, & Kim C. (2021). Deep learning model enables the discovery of a novel immunotherapeutic agent regulating the kynurenine pathway. Oncoimmunology, 10(1), 2005280.

+ Open protocol

+ Expand

Modulating Tumor Immunity with STB-C017

Check if the same lab product or an alternative is used in the 5 most similar protocols

Tumors were implanted via subcutaneous injection of 2 × 10 5 CT26 cells into the right ank of wild type BALB/c mice. When tumor volume reached >50 mm 3 , mice were orally administrated STB-C017 twice daily. Mice in the control group were orally treated with the same volume of PBS. For combination therapy, we also administered epacadostat orally (100 mg/kg, EPA, LEAPChem) twice daily. For the cell depletion study, the mice received an intraperitoneal injection of 200 μg of anti-CD8 (clone 53-6.72, BioXCell) antibody every 3 days. For immune checkpoint blockade, each mouse received an intraperitoneal injection of anti-PD-1 (8 mg/kg, clone J43, BioXCell) or anti-CTLA-4 (4 mg/kg, clone 9D9, BioXCell) antibody at the given time points. The surviving mice with complete tumor regression were rechallenged with 2 × 10 5 CT26 or Renca cells in the left ank, and the tumor growth was monitored. The tumors were measured with a digital caliper, and tumor volumes were calculated using the following modi ed ellipsoid formula: 1/2 × (length × width 2 ). For survival analysis, the mice were euthanized when the tumor volume exceeded 2000 mm 3 or when the mice became moribund.

Kim J.H., Lee W.S., Lee H.J., Yang H., Lee S.J., Kong S.J., Je S., Yang H., Jung J., Cheon J.K., Kang B., Chon H.J., & Kim C. (2021). Deep Learning Model Enables the Discovery of a Novel Immunotherapeutic Agent Regulating the Kynurenine Pathway.

+ Open protocol

+ Expand

Immunotherapy for Orthotopic HCC Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

Fourteen days after tissue implantation, mice with an established orthotopic HCC tumor con rmed by magnetic resonance imaging (MRI, 3.0 Tesia, Signa Excite HDx; GE healthcare, Milwaukee, WI, USA) were randomized by tumor size to assure similar baseline tumor sizes across groups. For autochthonous HCC mouse models, the treatment was initiated 8 months after the injection of DENA. The tumor volume was calculated using the following formula: tumor volume (mm 3 ) = a × b 2 × 0.5, where a represents the longest diameter and b represents the shortest diameter. Mice were treated with DC-TEX (4×10 6 , intravenous injection, DCs pulsed with exosomes (40 µg/mL) for 48 h) and/or PD-1 Ab (200 µg, intraperitoneal injection, clone J43; BioXCell, West Lebanon, NH, USA).

Shi S., Wang C., Zhang C., Zhang W., Qin Y., & Niu Z. (2021). Combined Therapy with Dendritic Cell Loaded-Exosomes Supplemented with PD-1 Inhibition Have Superior Antitumor Effect in Hepatocellular Carcinoma.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!